Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 555

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 5
Chunk 555
---
 ​      ​        ​        ​   
------------------------------------------------------------------
​                                         As of December 31,      
​                                    2024          2023           
​                                    ​    $’000                   
Shanghai Hutchison Pharmaceuticals   ​    77,765            48,411
​
The following table shows the financial position of Shanghai Hutchison Pharmaceuticals as of the dates indicated.
​

           ​              ​        ​         ​          ​    
-------------------------------------------------------------
​                         ​                As of December 31,
​                         2024             2023              
​                         ​                             $’000
Current assets                   213,707              201,025
Non-current assets                67,561               73,939
Current liabilities            (126,154)            (179,649)
Non-current liabilities          (3,859)              (3,687)
Net assets                       151,255               91,628
​
​

Results of Operations
The following table sets forth a summary of our consolidated results of operations for the years indicated, both in absolute amounts and as percentages of our revenue. This information should be read together with our consolidated financial statements and related notes included elsewhere in this annual report. Our operating results in any period are not necessarily indicative of the results that may be expected for any future period.
​

                        ​                            ​       ​       ​      ​      ​        ​       ​      ​      ​        ​       ​      ​   
----------------------------------------------------------------------------------------------------------------------------------------------
​                                                    ​                                                                 Year Ended December 31,
​                                                    ​                      2024    ​                      2023    ​                      2022
​                                                            $’000             %            $’000             %            $’000             %
Revenue                                                    630,201         100.0          837,999         100.0          426,409         100.0
Cost of revenue                                          (348,884)        (55.4)        (384,447)        (45.9)        (311,103)        (73.1)
Research and development expenses                        (212,109)        (33.7)        (302,001)        (36.0)        (386,893)        (90.7)
Selling expenses                                          (48,617)         (7.7)         (53,392)         (6.4)         (43,933)        (10.3)
Administrative expenses                              ​    (64,296)    ​   (10